The immunotherapy drug Tecentriq (atezolizumab) was approved earlier this year by the U.S. Food and Drug Administration to treat patients with newly diagnosed non-small cell lung cancers (NSCLC), which comprise up to 85% of all lung tumors.
from WebMD Health https://www.webmd.com/lung-cancer/news/20201001/immunotherapy-drug-boosts-survival-for-lung-cancer-patients?src=RSS_PUBLIC
0 Comments:
Post a Comment